Clinical Trials Logo
  1. Home
  2. Adenoid Cystic Carcinoma
  3. NCT05774899

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Adenoid Cystic Carcinoma Clinical Trial

Official title:
A Phase 1/2 Study of CB-103 (Oral Pan-NOTCH Inhibitor) With Abemaciclib or Lenvatinib in Combination in Patients With NOTCH Activated Adenoid Cystic Carcinoma (CALCulus)

Clinical Trial Summary

The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: - CB-103 (an oral NOTCH pathway inhibitor) - Abemaciclib (CDK4/6 inhibitor) - Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))

Clinical Trial Description

This is a phase 2, open-label, non-randomized, parallel cohort, multicenter study investigating the novel pan-NOTCH inhibitor, CB-103, in combination with the CDK4/6 inhibitor, Abemaciclib, and CB-103 in combination with the multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), Lenvatinib for patients with advanced, incurable, or metastatic adenoid cystic carcinoma (ACC) with a Notch pathway activating mutation. Participants will be placed into one of two treatment groups: Cohort 1: CB-103 + Abemaciclib or Cohort 2: VEGFR TKI Lenvatinib + CB-103. The U.S. Food and Drug Administration (FDA) has not approved CB-103 as a treatment for any disease. The FDA has not approved Abemaciclib or Lenvatinib for advanced adenoid cystic carcinoma (ACC)), but it has been approved for other uses or cancer types. Study procedures include screening for eligibility, treatment visits, radiologic scans of tumors, and blood tests. Participation in this study is expected to last about 2 years or until disease progression, therapy intolerance, or participant withdrawal. It is expected that about 32 people will take part in this research study. Cellestia Biotech AG is supporting this research study by providing funding. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05774899
Study type Interventional
Source Dana-Farber Cancer Institute
Contact Glenn Hanna, MD
Phone 617-632-3090
Email Gjhanna@partners.org
Status Recruiting
Phase Phase 1/Phase 2
Start date June 1, 2023
Completion date June 1, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04973683 - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer Phase 1
Completed NCT01417143 - Dovitinib in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Recruiting NCT04801264 - Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 Early Phase 1
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Recruiting NCT02942693 - Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma Phase 2
Completed NCT00581360 - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT05553782 - Drug Screening Using Novel IMD in ACC and Salivary Cancers Early Phase 1
Completed NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT02775370 - A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT02780310 - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma Phase 2
Completed NCT04119453 - A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC) Phase 2
Active, not recruiting NCT02098538 - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01558661 - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Phase 2
Completed NCT01524692 - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma Phase 2
Recruiting NCT03556228 - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Phase 1
Recruiting NCT01192087 - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy Phase 1/Phase 2
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Completed NCT01152840 - Study of RAD001 in Adenoid Cystic Carcinoma Phase 2